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ABSTRACT
Objective: The aim of this study was to determine the antimicrobial susceptibility of Acinetobacter baumannii strains, 
which were isolated from nosocomial infections and compare the changes in resistance rates of isolates over time. 
Methods: Acinetobacter spp. strains isolated from hospitalized patients diagnosed with nosocomial infection at Cum-
huriyet University Hospital between 2007 and 2011 were included in the study. Isolate identification and antibiotic sus-
ceptibility test were performed using an automated system according to the Clinical and Laboratory Standards Institute 
guidelines. 
Results: In total, 454 Acinetobacter spp. strains were included in this study. A. baumannii was the most frequently iso-
lated Acinetobacter species. Imipenem and meropenem resistance were determined to be 31.9% and 33.7%, respectively, 
and 74.4%, 78.0%, 76.7%, 46.6%, 62.4%, 66.8%, 61.3% and 53.9% of isolates were resistant to piperacillin-tazobactam, 
ceftazidime, cefepim, amikacin, gentamicin, ciprofloxacin, levofloxacin and tetracycline respectively. The resistance rates 
of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) A. baumannii were 50.2%, 
28.5%, and 14.0%, respectively. Changes in MDR, XDR and PDR rates over time were examined. Importantly, PDR A. 
baumannii have been reached dangerous levels over time. 
Conclusion: A. baumannii is one of the most important pathogen, particularly in a nosocomial setting. Increasing re-
sistance rates of this group to all antibiotics will likely lead to increased treatment failure in the future. J Microbiol Infect 
Dis 2014;4(1): 7-12
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Nozokomiyal patojenlerde artan antimikrobiyal direnç; çok ilaca dirençli, yaygın ilaç 
dirençli ve tüm ilaçlara dirençli Acinetobacter baumannii
ÖZET
Amaç: Bu çalışmada nozokomiyal enfeksiyonlardan izole edilen Acinetobacter spp. suşlarının antimikrobiyal duyarlılık-
ları tespit edilerek yıllar içerisindeki direnç değişimlerinin karşılaştırılması amaçlanmıştır. 
Yöntemler: Çalışmamıza 2007-2011 tarihleri arasında Cumhuriyet Üniversitesi Hastanesinde tedavi gören ve nozoko-
miyal enfeksiyon tanısı konulan hastaların klinik örneklerinden izole edilen Acinetobacter spp. suşları alınmıştır. Suşların 
tanımlanması ve antimikrobiyal duyarlılık testleri Clinical and Laboratory Standards Institute önerilerine göre otomatize 
sistem kullanılarak yapılmıştır. 
Bulgular: Klinik örneklerinden izole edilen toplam 454 Acinetobacter spp. suşu çalışmaya dahil edilmiştir. A. baumannii 
en sık izole edilen Acinetobacter türü olarak saptandı. İmipenem ve meropenem dirençli suş oranı sırası ile % 31.9 ve % 
33.7 olarak saptanırken, piperasilin/tazobaktam, seftazidim, sefepim, amikasin, gentamisin, siprofloksasin, levofloksasin 
ve tetrasiklin direnç oranları sırası ile % 74,4, % 78.0, % 76.7, % 46.6, % 62.4, % 66.8, % 61.3 ve % 53.9 olarak saptandı. 
Çok ilaca dirençli (MDR), yaygın ilaç dirençli (XDR) ve tüm ilaçlara dirençli (PDR) A. baumannii oranları sırası % 50.2, % 
28.5 ve % 14.0 olarak bulundu. Yıllar içindeki MDR, XDR ve PDR suş oranları değişimleri incelendiğinde, özellikle PDR A. 
baumannii oranının tehlikeli düzeylerde arttığı görüldü.
Sonuç: A. baumannii nozokomiyal enfeksiyonlarda en önemli patojenlerden biridir ve tüm antibiyotiklere karşı artan 
direnç oranları gelecekte daha çok tedavi başarısızlıklarına neden olacağı muhtemeldir.
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INTRODUCTION
Nosocomial infections increase the length of hospi-
talization, raise overall health costs, and are a ma-
jor cause of death worldwide. In the United States 
nosocomial infections cause or contribute to 1.7 
million infections and 99.000 deaths annually.1 Aci-
netobacter species are one of the most important 
factors in nosocomial infection as they are resistant 
to  environmental  influences  and  have  developed 
resistance to various antibiotics,2 including third-
generation cephalosporins, aztreonam, piperacillin, 
and carbapenems.3,4 Recent studies suggest that 
Acinetobacter baumannii is becoming increasingly 
antibiotic resistant and virulent, creating a major 
nosocomial threat.5,6
Efficient infection control strategies are needed 
to prevent Acinetobacter nosocomial infections.2 
Susceptibility to antimicrobials varies among coun-
tries, centers, and even hospital departments. 
These differences may reflect varying antibiotic us-
age patterns, epidemiological conditions, and anti-
biotic control policies. Thus, it is important to con-
sider local surveillance data to choose antibiotics.7 
The main problem about Acinetobacter infections in 
hospitals is that, these infections could cause high-
er mortality among the critically ill patients and up-
ward trend in multidrug resistance. In this study, we 
aimed to determine the antimicrobial resistance and 
susceptibilities of Acinetobacter spp. strains which 
were isolated from patients with nosocomial infec-
tions and to investigate the changes in resistance 
rates over years.
METHODS
We investigated Acinetobacter spp. strains which 
were isolated from patients with nosocomial infec-
tions at the Training and Research Hospital of Cum-
huriyet University over a five-year period between 
May 2007 and December 2011. In total, 454 strains 
isolated from various patient specimens (165 respi-
ratory tract, 99 urine, 76 blood, 70 wound site, 14 
cerebrospinal fluid, nine drains, and 21 other) were 
included in this study. 
Patient specimens sent to the Clinical Micro-
biology Laboratories of the Training and Research 
Hospital at Cumhuriyet University were planted in 
Columbia agar containing 5% sheep-blood (Salu-
bris) and eosin methylene blue (EMB) agar (Salu-
bris) media and then incubated at for 24-48 hours at 
35°C. Colonies grown on Columbia and EMB agar 
media were transferred to Phoenix NMIC ID/82 and 
Phoenix UNMIC ID/82 panels (McFarland 0.5 BD 
Biosciences, Franklin Lakes, NJ, USA) according 
to the manufacturer’s instructions, and then their 
identification and antimicrobial susceptibilities were 
determined using the BD Phoenix 100 (BD Biosci-
ences) system.
The resistance and susceptibility of these 
strains  to  antimicrobials  (amikacin,  ceftazidime 
ciprofloxacin,  cefepime,  gentamicin,  imipenem, 
meropenem,  levofloxacin,  piperacillin-tazobactam, 
trimethoprim-sulfamethoxazol,  and  tetracycline) 
were retrospectively examined based on labora-
tory records. While the strain that was first isolated 
from the patients was included in the study, re-
peat isolates with (the same) phenotype from the 
same patient were excluded from the study. Only 
one isolate (collected from the infected site, simul-
taneous growth of blood cultures were ignored) of 
the strains isolated from different specimens of the 
same patients was included in the analysis. Among 
the patients who showed no growth in other body 
fluids (i.e., urine, respiratory tract, and wound site) 
and had only positive blood culture was included as 
growth in the blood.
Multidrug-resistant  (MDR)  A. baumannii was 
defined as the strain having acquired non-suscep-
tibility to at least one agent in three or more antimi-
crobial categories. Extensively drug-resistant (XDR) 
A. baumannii was defined as showing non-suscep-
tibility to at least one agent in all but two or fewer 
antimicrobial categories (i.e., bacterial isolates re-
mained susceptible to only one or two categories). 
Pandrug-resistant (PDR) A. baumannii was defined 
as non-susceptibility to all agents in all antimicrobial 
categories.8
The results were statistically analyzed using 
SPSS 15.0 (SPSS, Inc., Chicago, IL, USA) software 
and Epi Info 3.5.3 software programs (Centers for 
Disease Control and Prevention, Atlanta, GA, USA). 
Proportion comparisons for categorical variables 
were  conducted  using  Chi-square  tests,  Fisher’s 
exact test was used when data were sparse P <0.05 
was considered statistically significant. Chi-square 
test trend analyses were used to identify differences 
among resistance rates by year. Our study was con-
ducted upon approval of the Ethics Committee of 
Cumhuriyet University Hospital.
In addition to the periodic control of bacteri-
ology systems used in the Clinical Microbiology 
Laboratories of the Training and Research Hospital 
of Cumhuriyet University by internal quality control 
strains (ATCC 25922 Escherichia coli, ATCC 27853 
Pseudomonas aeruginosa, ATCC 700603 Klebsiella 
pneumoniae, ATCC 25923 Staphylococcus aureus, 
and ATCC 29212 Enterococcus faecalis), systems 
were inspected by UK NEQAS between 2002 and Çelik C, et al Increasing antimicrobial resistance in A. baumannii 9
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2008, they have been inspected by the College of 
American Pathologist (CAP) external quality control 
centers since 2008.
RESULTS
This study included 454 Acinetobacter spp. strains 
isolated from various clinical specimens of patients 
over a period of five years. While 196 (43.2%) of 
these strains were isolated from specimens of pa-
tients in the intensive care unit, 258 (56.8%) strains 
were isolated from patients hospitalized in other 
units. The numbers of strains isolated by year were 
found to be 63 in 2007, 84 in 2008, 90 in 2009, 124 
in 2010, and 93 in 2011.
In total, 386 of the 454 strains (85%) cultured 
in clinical samples were defined as A. baumannii 
and 68 strains (15%) were defined as other Acineto-
bacter species. Resistance distributions of A. bau-
mannii strains and Acinetobacter spp. other than A. 
baumannii are shown in Table 1. For all studied an-
tibiotics, statistically significant (p<0.05) resistance 
rates were found in A. baumannii strains compared 
with species other than A. baumannii.
The resistance distributions of A. baumannii 
strains and changes in their distributions by year 
are shown in Table 2 and Figure 1. Resistance to 
gentamicin, ceftazidime cefepime, piperacillin-
tazobactam, ciprofloxacin, levofloxacin, imipenem, 
meropenem, and tetracycline gradually increased 
over time. The annual changes in resistance rates 
against all antibiotics except amikacin were signifi-
cant. While major changes were not observed in 
MDR rates and XDR rates over the years, for PDR 
rates; the pattern was unpredictable (the resistance 
rates were 4.7% and 3.1% in 2007 and 2008 which 
then increased to 20% in 2009 and 2011) (Figure 1).
Table 1. Resistance distributions of Acinetobacter bau-
mannii strains and Acinetobacter species other than Aci-
netobacter baumannii between 2007-2011 years
Antibiotics A. baumannii
n (%)
Acinetobacter spp.
n (%)
p
Amikacin 180/386 (46.6) 2/68 (2.9) <0.001
Gentamicin 241/386 (62.4) 3/68 (4.4) <0.001
Ceftazidime 301/386 (78.0) 17/68 (25.0) <0.001
Cefepim 296/386 (76.7) 15/68 (22.1) <0.001
Imipenem 123/386 (31.9) 1/68 (1.5) <0.001
Meropenem 130/386 (33.7) 2/68 (2.9) <0.001
Ciprofloxacin 258/386 (66.8) 7/68 (10.3) <0.001
Levofloxacin 237/386 (61.3) 6/68 (8.8) <0.001
PTZ 287/386 (74.4) 12/68 (17.6) <0.001
TMP-SMZ 257/386 (66.6) 21/68 (30.9) <0.001
Tetracycline 208/386 (53.9) 14/68 (20.6) <0.001
PTZ= Piperacillin-tazobactam
TMP-SMZ = Trimethoprim-sulfamethoxazole
Table 2. The changes in the resistance distributions of A. baumannii strains by years (2007-2011) (n = 386)
Antibiotics/Years,
n (%)
2007
(n=43)
2008
(n=64)
2009
(n=82)
2010
(n=112)
2011
(n=86) p*-value
Amikacin 23 (53.5) 16 (25.0) 48 (59.3) 54 (48.2) 39 (45.3) 0.554
Gentamicin 23 (53.5) 34 (53.1) 59 (72.8) 61 (54.5) 64 (74.4) 0.04
Ceftazidime 24 (55.8) 46 (71.9) 67 (82.7) 93 (83.0) 71 (82.6) <0.001
Cefepim 20 (46.5) 48 (75.0) 70 (86.4) 89 (79.5) 69 (80.2) <0.001
CIP 11 (25.6) 26 (40.6) 67 (82.7) 87 (77.7) 67 (77.9) <0.001
LEV 10 (23.3) 21 (32.8) 57 (70.4) 83 (74.1) 66 (76.7) <0.001
Imipenem 4 (9.3) 7 (10.9) 30 (37.0) 39 (34.8) 43 (50.0) <0.001
Meropenem 2 (4.7) 9 (14.1) 32 (39.5) 42 (37.5) 45 (52.3) <0.001
TMP SMZ 22 (51.2) 43 (67.2) 45 (55.6) 75 (67.0) 72 (83.7) <0.001
Tetracycline 16 (37.2) 32 (50.0) 35 (43.2) 62 (55.4) 63 (73.3) <0.001
PTZ 20 (46.5) 41 (64.1) 68 (84.0) 87 (77.7) 71 (82.6) <0.001
CIP=Ciprofloxacin, LEV=Levofloxacin, TMP-SMZ=Trimethoprim-sulfamethoxazole, PTZ=Piperacillin/tazobactam 
p*= Chi-square test trend analysisÇelik C, et al Increasing antimicrobial resistance in A. baumannii 10
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Figure 1. The changes in the resistance distributions of A. baumannii strains to several antibiotics which include most 
commonly used for treatment of nosocomial Acinetobacter infections and the distributions of MDR, XDR and PDR rates 
by years (2007-20011)
PTZ: Piperacillin/tazobactam, CIP: Ciprofloxacin, LEV: Levofloxacin, MDR: Multidrug resistant, XDR: Extensively drug 
resistant, PDR: Pandrug resistant
tively.13 International studies have reported varying 
results from different centers. However, Acineto-
bacter species were shown to be highly resistant to 
antibiotics in all studies.14-19 In a study conducted in 
our country, the authors reported resistance rates 
of 65%, 80%, 98%, 92%, 100%, and 86% for imipe-
nem, amikacin, piperacillin-tazobactam, cefepime, 
ceftriaxone, tetracycline, and trimethoprim-sulfa-
methoxazol respectively.20 Yuce et al.21 reported re-
sistance rates of 98%, 95%, 84%, 90%, and 100% 
for ceftazidime, cefepime, meropenem, imipenem, 
ciprofloxacin  and  piperacillin-tazobactam  respec-
tively. Resistance rates obtained in these studies 
which were conducted in our country are also high. 
In our study ,examining the five-year average anti-
microbial resistance distributions of nosocomial A. 
baumannii strains, the lowest resistance was ob-
served for imipenem and meropenem (31.9% and 
33.7%) and with the highest resistance observed 
for  cefepime  and  ceftazidime  (76.7%  and  78%). 
Relatively low resistance values were obtained for 
species other than A. baumannii (Table 1). The high 
resistance rates reported in studies may be associ-
ated with the efficiency of specific infection control 
programs and antimicrobial agent usage policies as 
well as more favorable environmental conditions in 
countries in which lower resistance rates were re-
ported.
Carbapenems have been the first-line treatment 
for nosocomial gram-negative infections. However, 
DISCUSSION
Antimicrobial  resistance  keeps  increasing  among 
hospital-acquired  gram-negative  pathogens.  Par-
ticularly A. baumannii, P. aeruginosa, and Stenotro-
phomonas maltophilia display multiple resistances 
to various antibiotics; making therapy selection dif-
ficult.9 A. baumannii has become a major nosoco-
mial pathogen in many hospitals in various parts 
of the world. This infection is associated with con-
siderable mortality, and no satisfactory results can 
be achieved using empirical therapies due to A. 
baumannii’s rapidly-increasing resistance to treat-
ment.10,11
A. baumannii is one of the most common infec-
tion-causing isolate among Acinetobacter species 
limiting treatment options due to its high antibiotic 
resistance.12 Our study showed that Acinetobacter 
strains, which were cultured from clinical samples, 
increased  in  number  each  year  and  that  85%  of 
strains cultured in literature medium were found to 
be A. baumannii.
Clinical studies report increasing resistance 
rates of A. baumannii, which is a factor in nosocomi-
al infections.5,6 A worldwide study including 25 coun-
tries and 99 centers between 2002 and 2004 report-
ed that resistance rates to Acinetobacter species 
were 24%, 25% 48%, 60%, 60%, and 72% for me-
ropenem, for imipenem, gentamicin, ciprofloxacin, 
piperacillin-tazobactam, and ceftazidime respec-Çelik C, et al Increasing antimicrobial resistance in A. baumannii 11
J Microbiol Infect Dis   www.jmidonline.org   Vol 4, No 1, March 2014
carbapenems have been showing reduced efficien-
cy as a result of increasing worldwide resistance 
to carbapenems as well as the emergence of PDR 
strains resistant to all drugs other than MDR and 
colistin and due to the increase in their numbers.6 In 
two European multi-center studies covering two dif-
ferent periods, imipenem resistance was shown to 
have increased from 25% to 40%, with meropenem 
resistance increasing from 24% to 35%.13,22 Car-
bapenem resistance poses a major problem for Tur-
key compared with other European countries.23 In 
a study by Alp et al.24 in our country, imipenem and 
meropenem resistance were reported to be 51% 
and 54%, respectively, for A. baumannii strains. 
In our study, a review of the distributions by year 
revealed developed that resistance to carbapen-
ems developed at an alarming rate. In 2007 the A. 
baumannii resistance to imipenem and meropenem 
was found to be 9.3% and 4.7%, respectively, while 
these resistance rates had respectively increased 
to 50.0% and 52.3% in 2011. 
It is commonly known that MDR and PDR strain 
rates are high in nosocomial A. baumannii infec-
tions.25,26 Joung et al.27 found the MDR and PDR re-
sistance rates to be 60.3% and 15.5%, respectively. 
Aimsaad et al.28 reported these rates to be 67.5% 
and 21.1%, respectively. In a study conducted in 
our country, Eser et al.20 reported the MDR Acineto-
bacter antibiotic resistance rate to be 41%. A review 
of resistance distributions of antibiotics used in our 
study over a period of five years showed increas-
ing rates of MDR and PDR strains. Particularly, 
the 4.7% PDR strain rate in 2007 was found to be 
20.9% in 2011. These resistance rates are consid-
ered indicators of a gradual increase in difficulties 
treating Acinetobacter infections.
Colistin is an older antibiotic that has recently 
been used for treating PDR microorganisms. Due-
nas et al.29  reported  that  98%  of  Acinetobacter 
strains were susceptible to colistin under in vitro 
conditions. Minimum inhibitory concentration levels 
should be determined when these drugs are used 
for treatment purposes. Clinical studies have re-
vealed that colistin is efficient for treating many mul-
tidrug-resistant gram-negative bacterial infections, 
and that it is a reliable treatment option against 
MDR, XDR or PDR strains.30-32 In our study, we did 
not conduct an antimicrobial susceptibility test for 
colistin that included broth microdilution and/or E-
test methods. 
There are some limitations of our study. First 
of all, the numerous studies have been investigat-
ing antibiotics such as colistin that were old but 
gained renewed importance in treatment of MDR A. 
baumannii isolates. Antimicrobial susceptibility re-
sults of colistin could not be given and we think that 
this condition compose the major deficiency of our 
study.  Furthermore,  although  additional  methods 
were used for antimicrobial susceptibility in some 
studies especially investigate MDR strains, we did 
not perform additional antimicrobial susceptibility 
test such as E-test due to our retrospective design.
Different antibiotic-resistance rates of Acineto-
bacter strains have been reported worldwide. Previ-
ous studies generally reveal high resistance rates 
which on the rise. These are raising concerns re-
garding the treatment of Acinetobacter infections. 
Our five-year local data can be used particularly in 
considering nosocomial Acinetobacter infections 
in order to create successful empirical treatment 
models and effectively prevent the spread of such 
microorganisms. Further studies are needed to ex-
amine colistin which found to be susceptible even 
in PDR strains under in vitro conditions, as well as 
new treatment options.
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